Brazilian network for HIV Drug Resistance Surveillance (HIV-BresNet): a survey of treatment-naive individuals

Página do item simplificado
dc.citation.issue3
dc.citation.volumev. 21
dc.contributor.authorArruda, Monica B.
dc.contributor.authorBoullosa, Lidia T.
dc.contributor.authorCardoso, Cynthia C.
dc.contributor.authorda Costa, Carolina M.
dc.contributor.authorAlves, Carlos R. B.
dc.contributor.authorde Lima, Shirlene T. S.
dc.contributor.authorKaminski, Helena T.
dc.contributor.authorAleixo, Agdemir W.
dc.contributor.authorEsposito, Ana O. P.
dc.contributor.authorCavalcanti, Ana M. S.
dc.contributor.authorRiedel, Maristela
dc.contributor.authorCouto-Fernandez, Jose C.
dc.contributor.authorFerreira, Selma B.
dc.contributor.authorde Oliveira, Ivi C. M.
dc.contributor.authorPortal, Loreci E.
dc.contributor.authorWolf, Hilda H. C.
dc.contributor.authorFernandes, Sandra B.
dc.contributor.authorPardini, Maria I. de M. C.
dc.contributor.authorFeiteiro, Manoel V. C.
dc.contributor.authorTolentino, Fernanda M.
dc.contributor.authorDiaz, Ricardo Sobhie [UNIFESP]
dc.contributor.authorLopes, Giselle I. S. L.
dc.contributor.authorFrancisco, Roberta B. L.
dc.contributor.authorVeras, Nazle M. C.
dc.contributor.authorPires, Ana F.
dc.contributor.authorFranchini, Miriam
dc.contributor.authorMesquita, Fabio
dc.contributor.authorTanuri, Amilcar
dc.coverageChichester
dc.date.accessioned2020-07-20T16:31:19Z
dc.date.available2020-07-20T16:31:19Z
dc.date.issued2018
dc.description.abstractIntroduction: In Brazil, more than 487,450 individuals are currently undergoing antiretroviral treatment. In order to monitor the transmission of drug-resistant strains and HIV subtype distribution in the country, this work aimed to estimate its prevalence and to characterize the nationwide pretreatment drug resistance in individuals recently diagnosed with HIV between 2013 and 2015. Methods: The HIV threshold survey methodology (HIV-THS, WHO) targeting antiretroviral-naive individuals with recent HIV diagnosis was utilized, and subjects were selected from 51 highly populated cities in all five Brazilian macroregions. The HIV pol genotypic test was performed by genomic sequencing. Results: We analysed samples from 1568 antiretroviral-naive individuals recently diagnosed with HIV, and the overall transmitted drug resistance (TDR) prevalence was 9.5% (150 sequences). The regional prevalence of resistance according to Brazilian geographical regions was 9.4% in the northeast, 11.2% in the southeast, 6.8% in the central region, 10.2% in the north and 8.8% in the south. The inhibitor-specific TDR prevalence was 3.6% for nucleoside reverse transcriptase inhibitors (NRTIs), 5.8% for non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 1.6% for protease inhibitors (PIs)en
dc.description.abstract1.0% of individuals presented resistance to more than one class of inhibitors. Overall, subtype B was more prevalent in every region except for the southern, where subtype C prevails. Conclusions: To the best of our knowledge, this is the first TDR study conducted in Brazil with nationwide representative sampling. The TDR prevalence revealed a moderate rate in the five Brazilian geographical regions, although some cities presented higher TDR prevalence rates, reaching 14% in Sao Paulo, for example. These results further illustrate the importance of surveillance studies for designing future strategies in primary antiretroviral therapy, aiming to mitigate TDR, as well as for predicting future trends in other regions of the globe where mass antiretroviral (ARV) treatment was implemented.en
dc.description.affiliationUniv Fed Rio de Janeiro, Lab Virol Mol, Dept Genet IB, Rio De Janeiro, RJ, Brazil
dc.description.affiliationFdn Med Trop Amazonas, Manaus, Amazonas, Brazil
dc.description.affiliationLAPI Univ Fed Bahia, Hosp Univ Prof Edgar Santos, Lab Pesquisa, Salvador, BA, Brazil
dc.description.affiliationLab Cent Saude Publ Ceara Lacen CE, Fortaleza, Ceara, Brazil
dc.description.affiliationLab Cent Saude Publ Dist Fed, Setor Grandes Areas Norte SGAN 601, Brasilia, DF, Brazil
dc.description.affiliationUniv Fed Minas Gerais UFMG, Fac Med, Lab Imunol & Biol Mol DIP, Belo Horizonte, MG, Brazil
dc.description.affiliationLab Cent Saude Publ Mato Grosso Sul, Campo Grande, MS, Brazil
dc.description.affiliationLab Cent Saude Publ Pernambuco, Recife, PE, Brazil
dc.description.affiliationLab Municipal Curitiba, Curitiba, PR, Brazil
dc.description.affiliationFiocruz MS, Lab AIDS & Imunol Mol, Dept Imunol, Rio De Janeiro, RJ, Brazil
dc.description.affiliationUniv Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Lab Carga Viral, Rio de Janeiro, RJ, Brazil
dc.description.affiliationInst Biol Exercito, Rio De Janeiro, RJ, Brazil
dc.description.affiliationLab Cent Saude Publ Rio Grande Sul, Porto Alegre, RS, Brazil
dc.description.affiliationLab Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil
dc.description.affiliationLab Cent Saude Publ Santa Catarina, Florianopolis, SC, Brazil
dc.description.affiliationUNESP, Lab Biol Mol Hemocentro Botucatu, Fac Med, Botucatu, SP, Brazil
dc.description.affiliationUniv Estadual Campinas, Lab Pesquisa AIDS, Hosp Clin, Campinas, SP, Brazil
dc.description.affiliationInst Adolfo Lutz Sao Jose do Rio Preto, Lab Biol Mol, Sao Jose Do Rio Preto, SP, Brazil
dc.description.affiliationUniv Fed Sao Paulo UNIFESP, Escola Paulista Med, Lab Retrovirol, Sao Paulo, SP, Brazil
dc.description.affiliationInst Adolfo Lutz Cent, Lab Retrovirus, Ctr Virol, Nucleo Doencas Sanguineas & Sexuais, Sao Paulo, SP, Brazil
dc.description.affiliationMinist Saude, Dept Vigilancia Prevencao & Controle DST AIDS & H, Setor Adm Fed Sul SAFS 02, Secretaria Vigilancia Saude, Brasilia, DF, Brazil
dc.description.affiliationUniv Brasilia, Programa Pos Grad Saude Colet, Fac Med, Fac Ciencias Saude, Brasilia, DF, Brazil
dc.description.affiliationUniv Sao Paulo, Fac Med, Sao Paulo, SP, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo UNIFESP, Escola Paulista Med, Lab Retrovirol, Sao Paulo, SP, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipBrazilian Ministry of Health
dc.description.sponsorshipIDBMH: TC 298/12
dc.format.extent-
dc.identifierhttp://dx.doi.org/10.1002/jia2.25032
dc.identifier.citationJournal Of The International Aids Society. Chichester, v. 21, n. 3, p. -, 2018.
dc.identifier.doi10.1002/jia2.25032
dc.identifier.fileWOS000429006000001.pdf
dc.identifier.issn1758-2652
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/55874
dc.identifier.wosWOS:000429006000001
dc.language.isoeng
dc.publisherJohn Wiley & Sons Ltd
dc.relation.ispartofJournal Of The International Aids Society
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHIVen
dc.subjectHIV drug resistanceen
dc.subjectpretreatment HIV drug resistanceen
dc.subjectprimary antiretroviral resistanceen
dc.subjectantiretroviral resistanceen
dc.subjectHIV Drug Resistance Surveillanceen
dc.titleBrazilian network for HIV Drug Resistance Surveillance (HIV-BresNet): a survey of treatment-naive individualsen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000429006000001.pdf
Tamanho:
512.62 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos